4.7 Article

The effects of long-term treatment with metrifonate, a cholinesterase inhibitor, on cholinergic activity, amyloid pathology, and cognitive function in APP and PS1 doubly transgenic mice

期刊

EXPERIMENTAL NEUROLOGY
卷 173, 期 2, 页码 196-204

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1006/exnr.2001.7819

关键词

Alzheimer's disease; amyloid; presenilin; transgenic mouse; metrifonate; cholinesterase inhibitor; hippocampus; spatial learning; spatial memory

向作者/读者索取更多资源

Recent studies in cell cultures have shown that modulating the cholinergic activity can influence the processing and metabolism of amyloid precursor protein (APP). To investigate whether acetylcholinesterase inhibitors (ChEIs) could decrease production of amyloid beta-peptide (Abeta) and slow down the accumulation of Abeta also in vivo, we chronically administered metrifonate (100 mg/kg, po), a second-generation ChEI, to 7-month-old doubly transgenic APP+PS1 mice and their nontransgenic littermate controls for 7 months. Behavioral studies, including open field test, T maze, and water maze, were conducted after 6 months treatment with metrifonate, and the mice were sacrificed at the age of 14 months for biochemical and histological analyses. The long-term treatment with metrifonate failed to inhibit the marked overproduction and deposition of Abeta in the APP+PS1 mice; in contrast, it increased both Abeta40 and Abeta42 levels in the hippocampus. However, the Abeta42 to 40 ratio was significantly reduced by the treatment. In addition, the number of amyloid plaques in the hippocampus did not differ between the treatment and the control groups. Tolerance to cholinesterase inhibition might be induced in the mouse brain because the inhibition rate of AChE was attenuated from about 80 to 50% during the experiment in both APP+PS1 and nontransgenic mice. The metrifonate treatment did not affect cognitive testing parameters but reduced swimming speed and locomotor activity in both genotypes. Our results do not support the idea that ChEls would slow down the progression of amyloid pathology in Alzheimer's disease. (C) 2002 Elsevier Science (USA).

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据